& Zimring, J
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors
Wegovy went through the new drug application pathway, with batch-level quality, potency, and consistency requirements behind it
Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca plc, Boehringer Ingelheim, Amgen Inc., Pfizer Inc., Device Platform Developers and Design Houses, Ypsomed AG (UnoPen, YpsoMate, ServoPen, SmartPilot), SHL Medical, Owen Mumford (Aidaptus, Autoject) and Others
Outcomes of interest included weight, body mass index (BMI), estimated glomerular filtration rate, blood pressure, fasting blood sugar, glycated hemoglobin (HbA1c), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and the urinary albumin to creatinine ratio (ACR)